NS002 Epinephrine:
Next-Generation Treatment for Anaphylaxis

NS002 is Nasus Pharma’s epinephrine intranasal powder candidate in development for the treatment of anaphylaxis. With phase 2 data demonstrating faster and higher absorption than the EpiPen®, NS002 is poised to transform a market underserved by the current bulky needle-based autoinjectors and nasal sprays with a short shelf life.
NS002 hero image

Anaphylaxis:
A Time-Critical Medical Emergency

  • Anaphylaxis is a severe allergic reaction that is fatal in ~1% of cases1

  • The standard of care for anaphylaxis is Epinephrine – this is typically self-administered via an Epinephrine auto-injector (EAI) or given via intramuscular (IM) injection by a healthcare provider

  • Quick Epinephrine delivery can make the difference between life and death

Faster is better: therapeutic threshold of 100pg/ml6 epinephrine is required to begin resolving anaphylaxis

SERIOUS PATIENT DISCOMFORT

5 MINUTES
TYPE I SEVERE ALLERGIC REACTION
  • Hypotension, dizziness, faintness
  • Rhinitis, watery red eyes
  • Rashes, itching (urticaria)
  • Rapid swelling (angioedema) including lips, tongue, throat
  • Difficulty breathing
  • Abdominal and chest pain, vomiting

HIGHER RISK OF HOSPITALIZATION AND DISEASE PROGRESSION3,4,5

15 MINUTES
LIKELIHOOD OF LIFE-THREATENING REACTION

Time to respiratory arrest or shock:2

    • FOOD ALLERGY: 30–35 minutes
    • INSECT STING ALLERGY: 10–15 minutes
    • DRUG ALLERGY: <10 minutes (Mortality in drug anaphylaxis is 6 times higher compared to other causes)6
15-30 MINUTES
ANAPHYLAXIS
  • Sudden drop in blood pressure leads to anaphylactic shock and cardiovascular failure
  • Airways narrow blocking breathing, leading to loss of consciousness
  • Possible death

Sources:

  1. Cantor Fitzgerald Research; Reber et al. 2017 J Allergy Clin Immunol; Allergy and Asthma Network; Nguyen et al. 2021 Int J Mol Sci; Munoz-Cano et al. 2017 Front Immunol
  2. Resuscitation Council (UK). Emergency treatment of anaphylaxis: guidelines for healthcare providers. Resuscitation Council (UK); 2021. Accessed September 6, 2025. https://www.resus.org.uk/sites/default/files/2021-05/Emergency%20Treatment%20of%20Anaphylaxis%20May%202021_0.pdf
  3. JF Philips et al. Allergy Asthma Proc (2011),
  4. JT Fleming et al. J Allergy Clin Immunol Pract (2014),
  5. E. Andrew et al. Prehospital Emergency Care (2018),
  6. Yu RJ et al. J Allergy Clin Immunol Pract. (2021) 7. Clutter WE, Bier DM, Shah SD, Cryer PE. Epinephrine plasma metabolic clearance rates and physiologic t hresholds for metabolic and hemodynamic actions in man. J Clin Invest. 1980;66(1):94-101. doi:10.1172/JCI109840

NS002 Designed to Address the Limitations of Intramuscular Epinephrine

Adult Epipen Size 15cm

Autoinjectors1 with a 12–18 month shelf-life

Large and bulky to carry2

Many patients avoid autoinjectors due to a fear of needles3

Nasus bottle Size 8cm

The proposed solution: NS002

Product candidate aims to offer a needle-free solution, longer shelf-life, easily administered by trained professionals and patients alike, potentially delivering greater and faster drug absorption, portable and convenient to carry alternative to EpiPen®

Sources:

  1. Cantor Fitzgerald Research; Kaplan et al. 2023 AAAAI Annual Meeting; Census.Gov; CDC.Gov; Payroll.Org
  2. Cantor Fitzgerald Research; Market Watch; Kaplan et al. 2023 AAAAI Annual Meeting
  3. Cantor Fitzgerald Research; Lowenthal et al. 2023 AAAAI Annual Meeting; Asthma and Allergy Foundation of America; Brooks et al. 2017 Ann Allergy Asthma Immunol; Fleming et al. 2015 J Allergy Clin Immunol Pract; McMurty et al. 2015 Clin J Pain could not verify references

NS002: Summary of Phase 2 Results:
NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors

PK Parameters
EpiPen®
NS002 4 mg
Cmax (mean) (pg/mL)
360
477
Tmax (median) (minutes)
15
10
AUC 0-10 min (h/pg/mL) 
966
1988
AUC 0-30 min (h/pg/mL)
4550
7228
T1001 (pg/mL) (median/mean) (minutes)
9
4/5
% of patients reaching 100 pg
55% (at 6 minutes)
91% (at 6 minutes)
    • NS002 reached the hemodynamic therapeutic plasma threshold faster than the EpiPen® 
    • Maximum epinephrine absorption (tmax) achieved significantly faster compared to EpiPen®
    • Nasax powder was well tolerated with transient mild symptoms

    • No findings at the nasal examinations

    • No serious adverse events
Explore Our Pipeline
Scroll to Top
Secret Link